Raymond James Financial Services Advisors, Inc. Halozyme Therapeutics, Inc. Transaction History
Raymond James Financial Services Advisors, Inc.
- $73.5 Billion
- Q3 2024
A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 16,353 shares of HALO stock, worth $953,216. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,353Holding current value
$953,216% of portfolio
0.0%Shares
8 transactions
Others Institutions Holding HALO
# of Institutions
545Shares Held
124MCall Options Held
668KPut Options Held
259K-
Black Rock Inc. New York, NY17.6MShares$1.03 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$774 Million0.01% of portfolio
-
State Street Corp Boston, MA7.18MShares$419 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.17MShares$243 Million4.34% of portfolio
-
Bank Of America Corp Charlotte, NC3.45MShares$201 Million0.01% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.12B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...